AIM ImmunoTech says Ampligen featured in medical journal as potential treatment for cancer patients infected with SARS-CoV-2

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) reports that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential treatment option for cancer patients infected with SARS-CoV-2.  In a statement, the company said the study’s authors stated that Ampligen has the potential to reduce the severity of the deadly respiratory disease COVID-19, which has so far caused more than 3.7 million deaths globally.   READ: AIM ImmunoTech extends pact with Shenzhen Smoore Technology to develop Ampligen as inhalation therapy for coronavirus According to the data presented in the publication, the authors wrote that “Rintatolimod [Ampligen] activated the innate and the adaptive immune systems by activating a cascade of actions in human pancreatic cancer cells,” including: Stimulation of interferon regulatory factors and activation of the interferon signaling pathway; Production of immunomodulatory activity; and Induction of the expression of MHC class I and II histocompatibility. AIM noted that Cancers is a peer-reviewed, open-access journal of oncology published semi-monthly online by MDPI and the study’s authors include Dr C.H.J. van Eijck, the lead investigator for the Early Access Program at Erasmus Medical Center in The Netherlands, where Ampligen is being used to treat patients with late-stage pancreatic cancer. “I do think Ampligen fully deserves to be developed for potential approval in the treatment of viral infections, including COVID-19," said Dr van Eijck. "The stimulation of the innate immunity by Ampligen is potentially important in combating aggressive viral infections and could save many lives.” Additionally, AIM has been granted a patent by The Netherlands. The granted claims include, but are not limited to, the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors (i.e. pembrolizumab and nivolumab). The patent expires December 19, 2039, or 20 years from the date of filing. “AIM is extremely pleased with the tremendous progress we are making in the Netherlands to advance Ampligen as a therapeutic,” said AIM CEO Thomas Equels. “Prof. van Eijck and his team are preeminent in their field. The data they present is compelling. Also, this patent issuance by the Netherlands is another successful step in our drug development program.” Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham